Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients

Abstract

NA-treated CHB patients switched to sequential PegIFNα-2a achieved highly potent treatment termination safely.